Appendix 4E, Directors Report and Financial Statements
Filed with ASX · · 98 pages · English
Lodged with the ASX under Listing Rule 4.3A. Contents Results for Announcement to the Market Additional Information Directors’ Report Financial Report CSL Limited ###### ABN: 99 051 588 348 ###### Appendix 4E ###### Full-year ended 30 June 2017 ###### (Previous corresponding period: Year ended 30 June 2016) Results for Announcement to the Market Underlying Net Profit after Tax at Constant Currency
Earlier from CSL
- CSL Completes Acquisition of Majority Stake in Ruide
- CSL Response to Patent Infringement Complaint
- FDA approves CSL Berhings HAEGARDA
- CSL to Acquire Majority Stake in Chinese Plasma Fractionator
- Half Year Results Release
Later from CSL
- 2017 FY Results Announcement and Analysts Presentation
- CSL Behring Acquires US Biotech Company Calimmune
- FDA Approves Privigen for CIDP Indication
- New Debt Facilities
- CEOs AGM Presentation
Follow CSL into a list and get an email when it puts out news.
Follow CSL